News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Anthracyclines: To Give or Not to Give? – SABCS
Photo from SABCS/Twitter
Aug 30, 2023, 17:53

Anthracyclines: To Give or Not to Give? – SABCS

As SABCS wrote on X/Twitter:

“Anthracyclines: To Give or Not to Give?

Martine J. Piccart and Virginia F. Borges will debate this question in a special session at SABCS23 (December 6), moderated by Hal Burstein.”

For details click here.
Source: SABCS/Twitter

Anthracyclines cancer Hal Burstein Martine J. Piccart OncoDaily Oncology SABCS Virginia F. Borges
Special Coverage
Blog
Apr 1, 2025, 07:09
Virginia Galvín: Should critical medications be integrated into defense budgets?
Blog
Apr 1, 2025, 06:51
Kendra Paabo: The 3 worst words you can say to someone with cancer
Blog
Apr 1, 2025, 06:49
Ali Atoui: Honored to Receive the 2025 CHAMP Award from the American Society of Hematology
Drugs
Apr 1, 2025, 06:49
Tislelizumab (Tevimbra): What Patients need to know?
Blog
Apr 1, 2025, 06:34
Trainee Day provided a space for trainees to connect and grow within the EBMT community
Blog
Apr 1, 2025, 06:20
Abhishek Chatterjee: The inaugural Stryker Breast Care Oncoplastic Surgery course has finished
Insight
Apr 1, 2025, 04:51
MD Anderson Cancer Center broke ground on a new 470,000-square-foot facility in Sugar Land
Blog
Apr 1, 2025, 04:49
Katy Beckermann: Secondary Analysis of the TITAN Trial
Blog
Apr 1, 2025, 04:37
Akhil Santhosh: 4 year update of CheckMate 743 Study
Societies
Apr 1, 2025, 04:26
Join SIOP for "Establishing a Network of Hospital-Based Registries in Resource-Limited Settings" Meeting
Opinion
Apr 1, 2025, 04:05
To all my oncology colleagues - Self-care should be your top healthcare priority: Sami Mansfield
Drugs
Apr 1, 2025, 03:53
Tislelizumab (Tevimbra): Uses in Cancer, Side Effects, Dosage, Expectations, and More